Trial Profile
A multicenter, open-label, non-controlled, dose-escalation study in patients with relapsed/refractory multiple myeloma and non-Hodgkin's lymphoma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 14 Dec 2021
Price :
$35
*
At a glance
- Drugs Selinexor (Primary)
- Indications Multiple myeloma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Ono Pharmaceutical
- 01 Oct 2018 Status changed from not yet recruiting to recruiting.
- 23 Jul 2018 New trial record